Business Context and Reporting Period
Company: Teva Pharmaceutical Industries Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2002
Business Overview: Teva is a global pharmaceutical company and one of the world's largest generic drug manufacturers. Its operations are divided into two primary segments: Pharmaceuticals (finished dosage forms) and Active Pharmaceutical Ingredients (API). The company operates in North America, Europe, Israel, and other international markets. In 2002, Teva reported sales of $2.52 billion, with approximately 64% of revenue generated in North America.
Key Financial Metrics
| Metric (in millions USD) | 2002 | 2001 | 2000 |
|---|---|---|---|
| Net Sales | 2,518.6 | 2,077.4 | 1,749.9 |
| Gross Profit | 1,095.4 | 847.3 | 691.9 |
| Gross Margin | 43.5% | 40.8% | 39.5% |
| Operating Income | 524.0 | 366.3 | 250.6 |
| Net Income | 410.3 | 278.2 | 148.4 |
| Diluted EPS (per ADR) | $1.52 | $1.02 | $0.57 |
| Cash from Operations | 353.7 | 273.2 | 165.6 |
| Total Assets | 4,626.8 | 3,460.2 | 2,855.6 |
| Total Debt (Short + Long Term) | 1,899.9 | 1,453.4 | 1,155.4 |
| Working Capital | 1,377.2 | 1,439.8 | 825.1 |
Note: Total Debt includes $738.5 million in short-term debt (including $562.4 million in convertible debentures classified as current due to put options) and $1,161.4 million in long-term debt.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 21.2% to $2.52 billion, driven by organic growth in generic pharmaceuticals (notably the Q4 launch of generic Augmentin) and the successful expansion of Copaxone sales in Europe.
- Profitability: Net income surged 47.5% to $410.3 million. Operating income grew 43.1% to $524.0 million. Gross margins improved to 43.5% due to a favorable product mix and currency fluctuations.
- Acquisitions: Teva acquired Teva Classics (France) and Teva Pharmaceutical Fine Chemicals (Italy) in mid-2002, contributing approximately $28 million to 2002 sales. These acquisitions were funded with $156 million in cash.
- R&D Expenses: Net R&D expenses increased 53.9% to $165.0 million. This was due to higher gross spending on generic pipeline development and a decrease in third-party participation grants from partners like Aventis and Lundbeck.
- Debt Structure: In November 2002, Teva issued $450 million in 20-year convertible senior debentures at a 0.375% coupon. Additionally, $550 million of existing convertible debentures were reclassified from long-term to short-term debt due to a put option exercisable in October 2003.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Tax Rate: The effective tax rate for 2002 was 17%. Management estimates the 2003 tax rate to be in the range of 20%–23% due to the expiration of certain Israeli tax holidays on Copaxone income, though new benefits from a southern Israel facility are expected to begin in 2004.
- Product Pipeline: As of February 2003, Teva had 61 product registrations awaiting FDA approval in the U.S., representing over $42 billion in branded sales potential.
- Copaxone: Global sales of Copaxone grew 48% in 2002. The pre-filled syringe now accounts for 95% of U.S. prescriptions.
Risks and Contingencies
- Patent Litigation: Teva faces significant litigation risks regarding generic products launched prior to patent expiration ("at risk"). Notable cases include appeals by GlaxoSmithKline (GSK) regarding the generic Augmentin patent validity and trade secret allegations regarding the manufacturing strain used.
- Regulatory Environment: Changes in FDA policies regarding 180-day exclusivity and data exclusivity periods could impact the profitability of generic launches.
- Geopolitical Risk: Significant operations are located in Israel. The company notes potential adverse effects from acts of terrorism or hostilities in the Middle East, though it has implemented contingency plans to ensure supply continuity.
- Product Liability: Teva is involved in various product liability suits, including those related to "fen-phen" (Adipex-P) and DES, though management believes insurance coverage is adequate and no material provision is required.
Investor Verification Checklist
- Convertible Debt Repurchase: Verify the status of the $550 million convertible debentures due in 2003 and the potential cash outflow if bondholders exercise their put option.
- Augmentin Litigation Outcome: Monitor the appeal of the GSK patent infringement case regarding generic Augmentin, as an adverse ruling could result in significant damages and an injunction on sales.
- Tax Rate Sustainability: Confirm the 2003 effective tax rate against the 20%–23% guidance, given the expiration of Israeli tax holidays.
- Generic Pipeline Approvals: Track the FDA approval status of the 61 pending ANDAs to validate future revenue growth projections.
- Integration of Acquisitions: Assess the financial performance of Teva Classics and Teva Pharmaceutical Fine Chemicals to ensure they meet synergy expectations.